Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2000

View Archived Issues

Axcan discusses short-term objectives at Chase H&Q Annual Health Care Conference

Optic nerve regeneration pathway identified by BLSI collaborators

Peptide Therapeutics' C. difficile vaccine: positive phase I/II results

NIH and DuPont establish OncoMouse technology agreement

Access cleared to commence phase III OraDisc study in the U.K.

Pyrrole derivatives for viral conditions synthesized by RPR (Aventis)

Novel anticonvulsants remain major area of research at SmithKline Beecham

Schering-Plough investigates new treatments for Alzheimer's disease

Wide series of HIV protease inhibitors described by Vertex in recent patent

Procter & Gamble terminates merger discussions; Warner-Lambert still exploring alternatives

Search for effective and well-tolerated anxiolytics continues at MS&D

Novel COX-2 inhibitors obtained through conversion of NSAIDs

Chiron discloses inhibitors of GSK3 activity and their use

New growth hormone option increases patient convenience

New protein prenyltransferase inhibitors from Merck lacking a thiol moiety

Hamster study supports use of omapatrilat as alternative to ACE inhibitors in heart failure

UC Irvine investigators uncover clue to the cause of ALS

Licensing opportunity from NIH: transframe peptide inhibitors of viral protease

TAP files for U.S. marketing approval of broad-spectrum cephalosporin

Potent peripheral benzodiazepine receptor ligand is effective in mouse model of RA

Methylnaltrexone reverses opioid-induced constipation

North American Vaccine submits NeisVac-C for U.K. approval

Important drug warning issued for Ziagen regarding fatal hypersensitivity reactions

Pharmacopeia and Organon collaborate on IL-8 research

Micrologix Biotech commences phase I trial for acne therapy

ISIS-3521: phase I trial establishes MTD and supports phase II development

DepoMed and Elan finalize joint venture agreements

New therapeutic approach to PD: adenosine A2A receptor blockade with KW-6002

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...